Colesevelam for the management of Type 2 diabetes

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 2, 2009, Pages 187-194

  Marrs, Joel C ^a,b  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Bile acid sequestrant; Colesevelam; Diabetes; Dyslipidemia; Hyperglycemia

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; COLESEVELAM; COLESTILAN; COLESTYRAMINE; DIGOXIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EZETIMIBE; FENOFIBRATE; GLUCAGON LIKE PEPTIDE; GLUCOSE; INSULIN; MEGLITINIDE; METFORMIN; METOPROLOL; MEVINOLIN; PHENYTOIN; QUINIDINE; SIMVASTATIN; SULFONYLUREA; VALPROIC ACID; WARFARIN;

ADD ON THERAPY; ADJUVANT THERAPY; AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; DIABETIC PATIENT; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; DYSPHAGIA; ESOPHAGUS OBSTRUCTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INTESTINE OBSTRUCTION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PILOT STUDY; POSTMARKETING SURVEILLANCE; REVIEW; RHINOPHARYNGITIS; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION;

ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA;

EID: 67649088904     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250802709009     Document Type: Review

References (59)

1. International Diabetes Federation. Available from: http://www.idf.org [Accessed 14 October 2008]
2. American Diabetes Association. Diabetes facts and figures. 2007 . Available from: http://www.diabetes.org/diabetes-statistics.jsp
3. Centers for Disease Control and Prevention. National Diabetes fact sheet United States. 2007 . Avialable from: http://www.diabetes.org
4. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986 (Pubitemid 23307905)
5. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonlyureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853 (Pubitemid 28416718)
6. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23:B21-9 (Pubitemid 30185774)
7. Reasner CA. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. J Cardiovasc Pharmacol 2008;52:136-44 • Comprehensive review of managing diabetic patient cardiovascular co-morbidities.
8. Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study. BMJ 2000;321:405-412 (Pubitemid 30609442)
9. American Diabetes Association. Standards for medical care in diabetes - 2008. Diabetes Care 2008;31(Suppl 1):S12-54
10. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31:1-11 •• Expert consensus statement on the management of hyperglycemia in type 2 diabetes internationally.
11. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865 (Pubitemid 28416719)
12. Holman RR, Paul AK, Bethel MA, et al. 10-year follo-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
13. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(Suppl 1):1-68
14. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496-504 • Comprehensive review of lipid abnormalities in the diabetic patient.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
16. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239 (Pubitemid 38924592)
17. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289:2560-2571 (Pubitemid 37430158)
18. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. Diabetes Care 2007;30:162-172
19. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular disease: executive summary. Eur Heart J 2007;28:88-136
20. Nathan DM. Glycemic management of type 2 diabetes: how tight is right and how to get there. Arch Intern Med 2008;168:2064-66 • Expert discussion on the role of new therapies in the management of type 2 diabetes.
21. Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose lowering effects of welchol study (GLOWS):a randomized, double blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74-83 (Pubitemid 46414026)
22. Bays HE, Goldberg RB, Truitt K, et al. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin. Arch Intern Med 2008;168:1975-1983
23. Fonseca VA, Rosenstock J, Wang A, et al. Colesevelam HCL improves glycemic control and reduces ldl cholesterol in patients with inadequately controlled type 2 diabetes mellitus on sulfonylurea-based therapy. Diabetes Care 2008;31:1479-1484
24. Goldberg RB, Fonseca VA, Truitt KE, et al. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531-1540
25. Garg A, Gundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994;121:416-422
26. Yamakawa T, Takano T, Utsunomiya H, et al. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 2007;54:53-58 (Pubitemid 46481671)
27. Parsippany, NJ. Prescribing information. WelChol (colesevelam): Sankyo Pharma, October 12; 2008
28. Welchol (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes. Available from: http://www.drugs.com/newdrugs/ welchol-colesevelam-hclreceives-fda-approval-reduce-bloodglucose-adults-type-2- diabetes-810.html [Accessed October 14, 2008]
29. Naarden, Netherlands. Prescribing information. Cholestagel (colesevelam), The Netherlands: Genzyme Europe BV, 12 October; 2008
30. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 2002;25:1015-1021 (Pubitemid 41110487)
31. Pladevall M, Williams LK, Potts LA, et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004;27:2800-2805 (Pubitemid 39565040)
32. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393 (Pubitemid 36159355)
33. Resnik HE, Foster GL, Bardsley J, et al. Achievement of American diabetes association clinical practice recommendations among US adults with diabetes 1999-2002. Diabetes Care 2006;29:531-537
34. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previous diagnosed diabetes. JAMA 2004;292:335-342 (Pubitemid 38101606)
35. Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 2006;144:465-474
36. Mahley RW, Bersot TP. Drug Therapy for Hypercholesterolemia and Dyslipidemia. Eleventh edition. In: Brunton LL, Lazo JS, Parker K, et al., editors, Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2006
37. Bays HE, Goldberg RB. The forgotten bile acid sequestrants: is now a good time to remember. Am J Therap 2007;14:567-80 •• Comprehensive review of the proposed mechanisms of action for the use of colesevelam HCL in treating hyperglycemia.
38. Bays HE, Jones PH. Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease factors. Vasc Health Risk Manag 2007;3:733-742 (Pubitemid 350104127)
39. Bays HE, Dujovne C. Colesevelam HCL: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003;4:779-790
40. Staehls B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007;67:1383-92 •• Comprehensive discussion on the use of bile acid sequestrants for several mechanisms in the management of type 2 diabetes. (Pubitemid 47026388)
41. Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J 2006;25:1419-1425
42. Yamagata K, Daitoku H, Shimamoto Y, et al. Bile acids regulate gluconeogenic gene expression via small heterdimer partner-mediated repression of hepatocyte nuclear factor 4 and foxo1. J Biol Chem 2004;279:23158-23165 (Pubitemid 38685621)
43. Ma K, Saha PK, Chan L, et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006;116:1102-1109
44. Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 2005;146:984-991 (Pubitemid 40289284)
45. Steffensen KR, Gustafsson JA. Putative metabolic effects of the liver X receptor (LXR). Diabetes 2004;53(Suppl 1):S36-42 (Pubitemid 38168691)
46. Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann Pharmacother 2001;35:898-907 (Pubitemid 32678716)
47. Steinmetz KL, Schonder KS. Colesevelam: potential uses for the newest bile resin. Cardiovasc Drug Rev 2005;23:15-30
48. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (Cholestagel):a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-1900 (Pubitemid 29424709)
49. Heller DP, Burke SK, Davidson DM, et al. Absorption of colesevelam hydrochloride in health volunteers. Ann Pharmacother 2002;36:398-403 (Pubitemid 34205309)
50. Knopp RH, Tsunehara C, Retzlaff BM, et al. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism 2006;55:1697-1703 (Pubitemid 44830137)
51. Donovan JM, Stypinski D, Stiles MR, et al. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drug Ther 2000;14:681-690 (Pubitemid 32217192)
52. Donovan JM, Kisicki JC, Stiles MR, et al. Effect of colesevelam on lovastatin pharmacokinetics. Ann Pharmacother 2002;36:392-397 (Pubitemid 34205308)
53. Jones MR, Baker BA, Mathew P. Effect of colesevelam HCL on single-dose fenofibrate pharmacokinetics. Clin Pharmacokinet 2004;43:943-950 (Pubitemid 39447035)
54. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001;110:352-360 (Pubitemid 32248724)
55. McKenny J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin 2005;21:1403-1412 (Pubitemid 41368572)
56. Rosenson RS, Abby SL, Jones MR. Colesevelam hcl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. Atherosclerosis 2008 (online 5 October, 2008)
57. Ferns G, Keti V, Griffin B. Investigation and management of hypertriglyceridaemia. J Clin Pathol 2008;61:1174-1183
58. Smellie WS. Cases in primary care laboratory medicine: hypertriglyceridaemia in diabetes. BMJ 2006;333:1257-1260
59. Fortson MR, Freedman SN, Webster PD. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol 1995;90:2134-2139